PMID- 31999898
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211112
IS  - 2372-952X (Print)
IS  - 2372-952X (Electronic)
IS  - 2372-952X (Linking)
VI  - 7
IP  - 1
DP  - 2020 Jan
TI  - Immunoglobulin E as a Biomarker for the Overlap of Atopic Asthma and Chronic 
      Obstructive Pulmonary Disease.
PG  - 1-12
LID - 10.15326/jcopdf.7.1.2019.0138 [doi]
AB  - Asthma-COPD overlap (ACO) is a common clinical syndrome, yet there is no single 
      objective definition. We hypothesized that immunoglobulin E (IgE) measurements 
      could be used to refine the definition of ACO. In baseline plasma samples from 
      2870 participants in the COPD Genetic Epidemiology (COPDGene(R)) study, we measured 
      total IgE levels and specific IgE levels to 6 common allergens. Compared to usual 
      chronic obstructive pulmonary disease (COPD), participants with ACO (based on 
      self-report of asthma) had higher total IgE levels (median 67.0 versus 42.2 
      IU/ml) and more frequently had at least one positive specific IgE (43.5% versus 
      24.5%). We previously used a strict definition of ACO in participants with COPD, 
      based on self-report of a doctor's diagnosis of asthma before age 40. This strict 
      ACO definition was refined by the presence of atopy, determined by total IgE > 
      100 IU/ml or at least one positive specific IgE, as was the broader definition of 
      ACO based on self-reported asthma history. Participants with all 3 ACO 
      definitions were younger (mean age 60.0-61.3 years), were more commonly African 
      American (36.8%-44.2%), had a higher exacerbation frequency (1.0-1.2 in the past 
      year), and had more airway wall thickening on quantitative analysis of chest 
      computed tomography (CT) scans. Among participants with ACO, 37%-46% did not have 
      atopy; these individuals had more emphysema on chest CT scan. Based on 
      associations with exacerbations and CT airway disease, IgE did not clearly 
      improve the clinical definition of ACO. However, IgE measurements could be used 
      to subdivide individuals with atopic and non-atopic ACO, who might have different 
      biologic mechanisms and potential treatments.
CI  - JCOPDF (c) 2020.
FAU - Hersh, Craig P
AU  - Hersh CP
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Zacharia, Soumya
AU  - Zacharia S
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Prakash Arivu Chelvan, Ram
AU  - Prakash Arivu Chelvan R
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Hayden, Lystra P
AU  - Hayden LP
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, 
      Massachusetts.
FAU - Mirtar, Ali
AU  - Mirtar A
AD  - Arasila Biotech, San Diego, California.
FAU - Zarei, Sara
AU  - Zarei S
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, 
      Massachusetts.
AD  - Arasila Biotech, San Diego, California.
FAU - Putcha, Nirupama
AU  - Putcha N
AD  - Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, 
      Baltimore, Maryland.
CN  - COPDGene(R) Investigators
LA  - eng
GR  - R01HL130512/GF/NIH HHS/United States
GR  - R01 HL130512/HL/NHLBI NIH HHS/United States
GR  - U01 HL089897/HL/NHLBI NIH HHS/United States
GR  - U01HL089856/GF/NIH HHS/United States
GR  - U01 HL089856/HL/NHLBI NIH HHS/United States
GR  - K23 HL123594/HL/NHLBI NIH HHS/United States
GR  - COPD Foundation Industry Advisory Committee/United States
GR  - U01HL089897/GF/NIH HHS/United States
GR  - P01HL132825/GF/NIH HHS/United States
GR  - Novartis/United States
GR  - R01 HL125583/HL/NHLBI NIH HHS/United States
GR  - P01 HL132825/HL/NHLBI NIH HHS/United States
GR  - R01HL125583/GF/NIH HHS/United States
GR  - K23HL123594/GF/NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Chronic Obstr Pulm Dis
JT  - Chronic obstructive pulmonary diseases (Miami, Fla.)
JID - 101635411
PMC - PMC7182380
OTO - NOTNLM
OT  - asthma
OT  - atopy
OT  - chest CT scan
OT  - chronic obstructive pulmonary disease
OT  - immunoglobulin E
COIS- Dr. Hersh reports grant support from the National Institutes of Health and 
      Novartis for this study. He reports grant support from Boehringer-Ingelheim and 
      personal fees from AstraZeneca and 23andMe outside of this study. None of the 
      other authors report any disclosures related to this study.
EDAT- 2020/01/31 06:00
MHDA- 2020/01/31 06:01
PMCR- 2019/12/20
CRDT- 2020/01/31 06:00
PHST- 2020/01/31 06:00 [entrez]
PHST- 2020/01/31 06:00 [pubmed]
PHST- 2020/01/31 06:01 [medline]
PHST- 2019/12/20 00:00 [pmc-release]
AID - 10.15326/jcopdf.7.1.2019.0138 [doi]
PST - ppublish
SO  - Chronic Obstr Pulm Dis. 2020 Jan;7(1):1-12. doi: 10.15326/jcopdf.7.1.2019.0138.